SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

ABSTRACT: Diabetic kidney disease not only has become the leading cause for ESRD worldwide but also, highly contributes to increased cardiovascular morbidity and mortality in type 2 diabetes. Despite increased efforts to optimize renal and cardiovascular risk factors, like hyperglycemia, hypertension, obesity, and dyslipidemia, they are often insufficiently controlled in clinical practice. Although current drug interventions mostly target a single risk factor, more substantial improvements of renal and cardiovascular outcomes can be expected when multiple factors are improved simultaneously. Sodium-glucose cotransporter type 2 in the renal proximal tubule reabsorbs approximately 90% of filtered glucose. In type 2 diabetes, the maladaptive upregulation of sodium-glucose cotransporter type 2 contribut

SUBMITTER: van Bommel EJM 

PROVIDER: S-EPMC5383382 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature